Background and aims Cocaine use disorder (CUD) is a significant public health issue for
which there is no Food and Drug Administration (FDA) approved medication. Drug …

Background Evidence suggests that the phenotypic expression of substance use disorders
(SUD) may be influenced by exposure to childhood maltreatment (CM). Objective To assess …

Background N-acetyl cysteine (NAC) appears promising as a treatment in patients with
substance use disorder (SUD) as it helps rebalance glutamate levels in the central nervous …

Cocaine use disorder (CUD) is a chronic neuropsychiatric disorder estimated to effect 1–3%
of the population. Activity-dependent neuroprotective protein (ADNP) is essential for brain …

It is recognized as a promising therapeutic strategy for cocaine use disorder to develop an
efficient enzyme which can rapidly convert cocaine to physiologically inactive metabolites …

There are currently no pharmacological treatments for cocaine use disorder. Recently there
has been a great deal of interest in the potential of psychedelic drugs such as psilocybin to …

Cocaine use disorder (CUD) is a prevalent neuropsychiatric disorder with few existing
treatments. Thus, there is an unmet need for the identification of new pharmacological …

Crack-cocaine dependence is a severe condition with a high mortality rate. This single case
study report details the first deep brain stimulation (DBS) trial targeting the sub-thalamic …

Background Detoxification is frequently recommended as a treatment for moderate to severe
Cocaine Use Disorder (CUD). However, the response to detoxification varies among …

We have recently reported sex differences in the plasma concentrations of lysophosphatidic
acid (LPA) and alterations in LPA species in patients with alcohol and cocaine use …